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Haploinsufficiency of the Shank3 gene, which en-
codes a scaffolding protein at glutamatergic synap-
ses, is a highly prevalent and penetrant risk factor
for autism. Using combined behavioral, electrophys-
iological, biochemical, imaging, and molecular ap-
proaches, we find that Shank3-deficient mice exhibit
autism-like social deficits and repetitive behaviors,
as well as the significantly diminished NMDA
receptor (NMDAR) synaptic function and synaptic
distribution in prefrontal cortex. Concomitantly,
Shank3-deficient mice have a marked loss of cortical
actin filaments, which is associated with the reduced
Rac1/PAK activity and increased activity of cofilin,
themajor actin depolymerizing factor. The social def-
icits and NMDAR hypofunction are rescued by inhib-
iting cofilin or activating Rac1 in Shank3-deficient
mice and are induced by inhibiting PAK or Rac1 in
wild-type mice. These results indicate that the aber-
rant regulation of synaptic actin filaments and loss of
synaptic NMDARs contribute to the manifestation of
autism-like phenotypes. Thus, targeting actin regula-
tors provides a strategy for autism treatment.
INTRODUCTION
Autism spectrum disorder (ASD) is a group of neurodevelopmen-
tal disorder characterized by impaired social communication
and repetitive and restricted behavioral patterns. Haploinsuffi-
ciency of the Shank3 gene due to deletion or de novo mutation
has been linked to autism in human genetics studies (Bonaglia
et al., 2001; Durand et al., 2007; Sebat et al., 2007; Betancur
and Buxbaum, 2013; De Rubeis et al., 2014) and animal model
investigations (Bozdagi et al., 2010; Wang et al., 2011; Pec¸a
et al., 2011; Kouser et al., 2013). Shank3 is a scaffolding protein
at postsynaptic density (PSD) of glutamatergic synapses and in-
cludes an N-terminal ankyrin repeat domain, a SH3 domain, a
PDZ domain that links to guanylate kinase-associated proteins,1400 Cell Reports 11, 1400–1413, June 9, 2015 ª2015 The Authorsa proline-rich domain containing Homer and Cortactin binding
regions, and a C-terminal SAM domain (Naisbitt et al., 1999).
Shank3 has been suggested to act as a master organizer of
the PSD because of its ability to interact with multiple key synap-
tic components including glutamate receptor complexes,
anchoring proteins, and actin cytoskeleton (Sheng and Kim,
2000; Hayashi et al., 2009). However, the molecular targets of
Shank3 causally linked to the ASD-like behavioral deficits are
largely unknown.
The NMDA-type glutamate receptor, a key PSD protein con-
trolling neural development and synaptic plasticity underlying
cognitive processes, is physically associated with Shank3 (Nais-
bitt et al., 1999; Ehlers, 1999). Recent evidence has implicated
NMDA receptor (NMDAR) dysfunction in ASD (Carlson, 2012).
Administration of NMDAR antagonists or NR1 deficiency in-
duces ASD-like social deficits in mice (Zou et al., 2008). Shank2
or Shank3-lacking mice exhibit impaired NMDAR-dependent
synaptic plasticity along with ASD-related behaviors (Wang
et al., 2011; Won et al., 2012; Kouser et al., 2013).
The NMDAR is closely tied to actin filaments through actin-
binding proteins (Wyszynski et al., 1997). The integrity of actin
cytoskeleton is critical for NMDAR membrane delivery and sta-
bility (Rosenmund and Westbrook, 1993; Allison et al., 1998),
as well as the plasticity of NMDAR-mediated synaptic responses
(Morishita et al., 2005). Shank3 is found to be located at the tip of
actin filaments and enhances its polymerization (Durand et al.,
2012), and Shank overexpression induces spine enlargement
in spiny excitatory neurons (Sala et al., 2001). In vivo Shank3
interactome analysis has identified several actin regulators
that bind to Shank3 (Han et al., 2013). Thus, it is conceivable
that Shank3 deficiency may disrupt actin dynamics, leading
to NMDAR hypofunction, which contributes to the ASD
symptoms.
A key player in the regulation of actin dynamics is Rac1, a
member of the family of RhoGTPases, which acts as amolecular
switch in intracellular signaling pathways. The activity of the
GTPases is regulated by guanine nucleotide exchange factors
(GEFs). Rac1 stimulates spine formation, dendrite initiation,
elongation, and branching complexity (Threadgill et al., 1997;
Ridley, 2006). The major downstream effectors of Rac1 are
p21-activated kinase (PAK) and LIM-domain containing protein
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Figure 1. Shank3-Deficient Mice Exhibit
Social Deficits and Repetitive Behaviors
(A) Western blots and bar graphs (mean ± SEM)
showing the loss of endogenous full-length
Shank3 (FL-Shank3) isoforms in the total cortical
lysates and postsynaptic density (PSD) fraction of
frontal cortex from heterozygous mice expressing
C-terminal deleted Shank3, Shank3+/DC. Anti-
bodies against Shank3 SH3 domain, PDZ domain,
or C-term were used. *p < 0.001, t test.
(B) Bar graphs (mean ± SEM) showing the time
spent investigating either the social (Soc1) or
nonsocial (NS1) stimulus in sociability testing
(phase 2) inmale wild-type (WT) versus Shank3+/DC
mice. *p < 0.001, WT versus Shank3+/DC; #p <
0.001, ##p < 0.01, Soc1 versus NS1, two-way
ANOVA.
(C) Bar graphs (mean ± SEM) showing the prefer-
ence index for investigating different stimuli at
three phases of sociability testing in WT versus
Shank3+/DC mice. *p < 0.001, t test.
(D) Bar graphs (mean ± SEM) showing the number
of midline crossing in locomotion tests, the time
spent in the center during open-field tests, the
latency to fall during rotarod tests, and the time
spent self-grooming in WT versus Shank3+/DC
mice. *p < 0.01, t test.
(E) Bar graphs (mean ± SEM) showing the time
spent investigating either the Soc1 or NS1 stimulus
in sociability testing (phase 2) in WTmice receiving
a PFC injection of either saline or APV (1 mM, 1 ml
each side). *p < 0.001, saline versus APV; #p <
0.001, ##p < 0.01, Soc1 versus NS1, two-way
ANOVA.
(F) Bar graphs (mean ± SEM) showing the prefer-
ence index for investigating different stimuli at
three phases of sociability testing in WT mice
receiving a PFC injection of either saline or APV.
*p < 0.01, t test.
See also Figure S1 and Movies S1, S2, and S3.kinase (LIMK), which facilitate actin filament assembly through
the phosphorylation and inactivation of cofilin (Sells et al.,
1997; Arber et al., 1998), a major actin depolymerizing factor
(Bamburg 1999; dos Remedios et al., 2003). Aberrant Rac1/
PAK/LIMK signaling could lead to abnormal neuronal connectiv-
ity and synaptic plasticity, as well as deficient cognitive and
emotional functioning (Hayashi et al., 2004; Golden et al.,
2013). Importantly, genetic analyses have revealed that intellec-
tual disability (Ramakers, 2002), autism (Gilman et al., 2011), and
schizophrenia (Fromer et al., 2014) all have enrichedmutations in
genes regulating actin filament network at glutamatergic synap-
ses, indicating that actin dysregulation is one common patho-
physiological mechanism for these disorders.
Our recent studies found that Shank3 knockdown in vitro led
to the reduced NMDAR function in cortical neurons via an
actin-dependent mechanism (Duffney et al., 2013). In the current
study, we examined whether the NMDAR hypofunction and
ASD-like behavioral deficits in autism models with Shank3 hap-
loinsufficiency are caused by the decreased Rac1/PAK signaling
and increased actin depolymerization by cofilin, and whether
manipulating actin regulators could rescue the synaptic and
behavioral deficiencies in this autism model.CRESULTS
Shank3-Deficient Mice Exhibit ASD-like Behaviors and
Impaired NMDAR Function in Prefrontal Cortex
To determine the impact of Shank3 deficiency on autism-like be-
haviors, we used heterozygous mice with C-terminal deleted
Shank3 (deletion of exon 21, which includes the Homer- and
Cortactin-binding domains), Shank3+/DC, since hemizygous mu-
tation in the Shank3 gene has been linked to autism and intellec-
tual disability (Bonaglia et al., 2001; Durand et al., 2007). Using
antibodies against Shank3 SH3 domain, PDZ domain, or
C-term (Figure 1A), we found that, compared to wild-type
mice, Shank3+/DC mice showed a significant knockdown of
the endogenous full-length Shank3 (FL-Shank3) isoforms
(190 kDa) in total and synaptosomal fraction of frontal cortical
lysates (50%–70% reduction, n = 7 pairs, p < 0.001, t test), hence
providing an excellent model for studying the impact of the loss
of naturally occurring Shank3 proteins. Interestingly, the C-term
deleted Shank3 protein (DC-Shank3, 90 kDa) can only be
found in total brain lysates, but not the synaptosomal fraction,
suggesting that DC-Shank3 has lost its synaptic distribution,
probably due to the lack of its binding to Cortactin/F-actin.ell Reports 11, 1400–1413, June 9, 2015 ª2015 The Authors 1401
Homozygous Shank3DC/DC mice had an even more prominent
loss of endogenous FL-Shank3 isoforms detected with the
three Shank3 antibodies (85% reduction, n = 4 pairs,
Figure S1A).
Juvenile male Shank3+/DC mice and age-matched wild-type
mice were subject to the three-chamber social interaction assay
(Wang et al., 2011; Won et al., 2012). Briefly, the test is
composed of three phases with various stimuli placed in each
of two side chambers. Phase 1 contains two identical nonsocial
stimuli (NS1 and NS1), phase 2 contains a nonsocial stimulus
(NS1) and a social stimulus (Soc1), and phase 3 contains a
known social stimulus (Soc1) and a novel social stimulus
(Soc2). The preference index for one stimulus over the other
stimulus in each phase was compared.
As shown in Figure 1B, during the presentation of both a social
and a non-social stimuli (Soc1-NS1, phase 2), wild-type mice
spent significantly more time exploring the social stimulus over
the non-social object, while Shank3+/DC mice showed a signifi-
cant loss of the preference for the social stimulus (WT social:
126.1 ± 6.8 s, WT nonsocial: 26.4 ± 1.6 s, n = 52; Shank3+/DC
social: 60.6 ± 3.0 s, Shank3+/DC nonsocial: 39.5 ± 1.8 s, n = 52,
F1,204 (interaction) = 100.8, p < 0.001, two-way ANOVA; see Movies
S1 and S2). The significantly reduced social preference index in
Shank3-deficient mice (Figure 1C, WT: 64.3% ± 1.9%, n = 52;
Shank3+/DC: 20.7% ± 2.5%, n = 52, p < 0.001, t test) suggests
an impairment of sociability. The social deficits in young male
Shank3+/DC mice were so evident that it led to 100% accuracy
in blind tests (i.e., where raters had no prior knowledge about
the genotypes). When presented with two identical non-social
stimuli (NS1-NS1, phase 1), no preference was observed in
either genotype (Figure 1C, WT: 1.3% ± 2.5%, n = 45;
Shank3+/DC: 1.6% ± 2.1%, n = 45, p > 0.05, t test). When
exposed to two social stimuli (Soc2-Soc1, phase 3), both
genotypes displayed similar preference for the novel over the
familiar social stimulus (Figure 1C, WT: 31.1% ± 2.3%, n = 46;
Shank3+/DC: 31.6% ± 2.3%, n = 49, p > 0.05, t test), suggesting
that Shank3-deficient mice have intact social novelty recognition
memory. Consistently, the impaired sociability (phase 2) in
Shank3+/DC mice was not due to deficits in novelty recognition,
because when animals were exposed to a social and a ‘‘novel’’
non-social stimuli (Soc1-NS2) in phase 2, a similar difference
on the preference index for the social stimulus over the non-
social stimulus was found between the two genotypes (WT:
56.1% ± 5.3%, n = 10; Shank3+/DC: 16.1% ± 5.8%, n = 12, p <
0.001, t test).
Homozygous Shank3DC/DC mice (juvenile male) also exhibited
significantly lower social preference (Soc1-NS1, phase 2) in the
three-chamber sociability tests (Figure S1B, WT: 59.7% ±
2.0%, n = 12; Shank3DC/DC: 24.2% ± 8.1%, n = 10, p < 0.001,
t test). Among the large number of animals we examined, the
majority of Shank3+/DC or Shank3DC/DC mice exhibited deficits
in the social preference, comparing to wild-type counterparts
(Figure S1C). Moreover, Shank3DC/DC mice had dramatically
reduced investigation time toward both social stimuli in phase 3
(Figure S1D, WT: 130.7 ± 8.0 s, n = 21; Shank3+/DC: 92.8 ± 9.4 s,
n = 21; Shank3DC/DC: 29.1 ± 6.0 s, n = 10, F2,49 = 25.7, p < 0.001,
ANOVA), indicating that they have either a social avoidance
phenotype or less social drive.1402 Cell Reports 11, 1400–1413, June 9, 2015 ª2015 The AuthorsWild-type and Shank3-deficient mice were also compared in
other behavioral tasks (Figure 1D). No differences were seen in
locomotion (midline crossing #, WT: 31.9 ± 5.0, n = 7,
Shank3+/DC: 29.6 ± 5.0, n = 9, p > 0.05, t test). Both genotypes
showed similar results in the open-field test (time in center,
WT: 15.5 ± 3.8 s, n = 11, Shank3+/DC: 13.0 ± 2.4 s, n = 11, p >
0.05, t test) and the rotarod test (latency to fall, WT: 40.0 ±
6.1 s, n = 12; Shank3+/DC: 47.1 ± 5.3 s, n = 14, p > 0.05, t test),
suggesting that anxiety level and motor coordination are normal
in Shank3-deficient mice. However, differences were evident in
self-grooming, with Shank3-deficient mice spending signifi-
cantly more time engaged in this repetitive behavior (WT:
21.4 ± 4.4 s, n = 25, Shank3+/DC: 93.1 ± 13.3 s, n = 22, p <
0.01, t test, see Movie S3).
To identify the cellular and molecular basis for the social
interaction behavior, we focused on prefrontal cortex (PFC), a
brain region controlling high-level executive functions, which
has been suggested as a key area mediating ASD-like
behaviors (Anderson et al., 1999; Hill, 2004). Given the data
implicating NMDAR dysfunction in ASD (Carlson, 2012), we
blocked NMDA receptors in PFC of wild-type mice and
examined their social interaction behavior. To do this, the
NMDAR antagonist APV was stereotaxically injected bilaterally
into prelimbic regions. As shown in Figure 1E, compared to
saline-injected mice, mice injected with APV displayed a
significant decrease of the preference for the social stimulus
over the non-social object in phase 2 of the three-chamber
social interaction assay (saline, social: 152.7 ± 10.0 s,
nonsocial: 36.0 ± 6.9 s, n = 6; APV, social: 92.3 ± 7.0 s,
nonsocial: 56.0 ± 6.5 s, n = 6, F1,20 (interaction) = 27.0, p <
0.0001, two-way ANOVA). The significant reduction of social
preference index in phase 2 by APV injection (Figure 1F, saline:
63.4% ± 4.4%, n = 6; APV: 27.0% ± 3.9%, n = 6, p < 0.01,
t test) suggests that NMDA receptors in PFC are crucial for
sociability.
Next, we examined NMDAR function in PFC of Shank3-defi-
cient mice, alterations of which may underlie the ASD-like social
deficits in these animals. Layer 5 PFC pyramidal neurons, which
showed the clearest deficits in autistic children (Stoner et al.,
2014), were selected for the recording of NMDAR-mediated
excitatory postsynaptic currents (EPSCs). As shown in Figure 2A,
NMDAR-EPSC induced by a series of stimulus intensities was
markedly reduced in Shank3+/DC mice (30%–40% decrease,
WT: n = 26, Shank3+/DC: n = 37). Two-way ANOVA analysis re-
vealed a significant main effect of genotype (F1,305 = 118.4, p <
0.001) and stimulation intensity (F4,305 = 26.6, p < 0.001). Post
hoc multiple comparison tests revealed that PFC neurons from
Shank3+/DC had significantly lower NMDAR responses than
those from WT mice (p < 0.01). In contrast, AMPAR-EPSC was
largely unchanged in PFC pyramidal neurons from Shank3-defi-
cient mice (Figure 2B, <5% decrease, WT: n = 18, Shank3+/DC:
n = 19, F1,175 (genotype) = 1.5, p > 0.05, two-way ANOVA). The
NMDAR- to AMPAR-EPSC ratio was significantly smaller in
PFC pyramidal neurons from Shank3-deficient mice than
those from age-matched wild-type mice (Figure 2C, WT:
0.71 ± 0.05, n = 12, Shank3+/DC: 0.52 ± 0.04, n = 14; p < 0.01,
t test). A smaller but significant reduction of NMDAR-EPSC
was also observed in hippocampal CA1 pyramidal neurons of
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Figure 2. Shank3-Deficient Mice Show
the Diminished NMDAR Synaptic Function
and Synaptic Distribution in Prefrontal
Cortex
(A and B) Input-output curves (mean ± SEM) of
NMDAR-EPSC (A) and AMPAR-EPSC (B) in
response to a series of stimulation intensities in
PFC pyramidal neurons from male WT versus
Shank3+/DC mice. *p < 0.01, ANOVA. Inset:
representative EPSC traces at different stimuli.
Scale bars, 40 pA, 100 ms (NMDA); 50 pA, 25 ms
(AMPA).
(C) Bar graphs (mean ± SEM) of the NMDAR- to
AMPAR-EPSC ratio in WT versus Shank3+/DC
mice. *p < 0.01, t test. Inset: representative
traces of NMDAR-EPSC and AMPAR-EPSC
recorded in the same PFC pyramidal neurons
from WT versus Shank3+/DC mice. Scale bar,
20 pA, 100 ms.
(D) Immunoblots showing the expression of
NMDAR and AMPAR subunits in the Triton-insol-
uble synaptosomal fraction or the total lysate of
frontal cortical slices from WT versus Shank3+/DC
mice.
(E) Quantification (mean ± SEM) of the alteration of
synaptosomal (normalized to PSD-95) and total
(normalized to Tubulin) glutamate receptors in
Shank3+/DCmice, compared toWTmice. *p < 0.01,
WT versus Shank3+/DC, t test.
See also Figures S2 and S3.Shank3+/DC mice (Figure S2A, WT: n = 19, Shank3+/DC: n = 17,
F1,170 (genotype) = 19.1, p < 0.05, two-way ANOVA). No significant
loss of NMDAR-EPSC was found in dorsal striatal medium spiny
neurons of Shank3+/DC mice (Figure S3A, <5% decrease, WT:
n = 13, Shank3+/DC: n = 15, F1,130 (genotype) = 0.5, p > 0.05, two-
way ANOVA). These data indicate thatShank3 deficiency causes
prominent NMDAR hypofunction in the PFC in vivo, consistent
with our findings in cortical cultures with Shank3 knockdown
(Duffney et al., 2013).
The selective loss of cortical NMDAR function in Shank3-
deficient mice could result from the reduced number of
NMDA receptors at synapses. To test this, we compared
subcellular distribution of glutamate receptors in PFC of
wild-type and Shank3-deficient mice. As shown in Figures 2D
and 2E, NR1 and NR2A subunits in the Triton-insolubleCell Reports 11, 1400–14synaptosome fraction of frontal cortical
tissues were significantly reduced in
Shank3+/DC mice (NR1: 43% ± 7%
decrease, NR2A: 36% ± 4% decrease,
n = 6 pairs, p < 0.01, t test), while synap-
tosomal NR2B, GluR1, and GluR2 sub-
units were largely unchanged (n = 6
pairs, p > 0.05, t test). No significant
changes were found on the total levels
of NR1, NR2A, NR2B, GluR1, and
GluR2 subunits in PFC of Shank3+/DC
mice (n = 14 pairs, p > 0.05, t test). The
reduced amount of NMDARs in the syn-
aptic pools suggests the loss of NMDARdelivery to the plasma membrane of PSDs in Shank3-deficient
conditions.
Shank3-Deficient Mice Exhibit Altered Rac1/PAK/
Cofilin Signaling and Dysregulated F-actin in Frontal
Cortex
Given the importance of Rac1 signaling and actin stability in
Shank3-regulated NMDAR membrane trafficking (Duffney
et al., 2013), we next examined whether actin regulators were
altered in Shank3-deficient mice. It has been shown that bPIX,
the guanine nucleotide exchange factor (GEF) for Rac1 that pro-
motes functional coupling of Rac1 and PAK (Manser et al., 1998),
interacts with Shank at excitatory synaptic sites (Park et al.,
2003). In the total lysates from prefrontal cortical slices of
Shank3+/DC mice (Figures 3A and 3B), the protein level of bPIX13, June 9, 2015 ª2015 The Authors 1403
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Figure 3. Shank3-Deficient Mice Exhibit
Decreased Rac1/PAK Signaling, Increased
Cofilin Activity, and Reduced Synaptic
F-actin in Prefrontal Cortex
(A) Immunoblots showing the expression of actin
regulators, such as bPIX (the GEF involved in Rac1
activation), Rac1, PAK1, p-PAK (active PAK1/2/3),
LIMK1, cofilin, p-cofilin (inactive cofilin), WAVE1,
and WAVE3 in total lysates from PFC of WT versus
Shank3+/DC mice.
(B) Quantification (mean ± SEM) of the alteration of
actin regulators in Shank3+/DC mice. *p < 0.01, WT
versus Shank3+/DC, t test.
(C) Immunoblots and quantification (mean ± SEM)
showing the alteration of actin regulators in the
cytosolic fraction of synapses from PFC of
Shank3+/DC mice. *p < 0.01, WT versus
Shank3+/DC, t test.
(D and E) Representative blots and quantification
(mean ± SEM) showing the active Rac1 (D: bPIX-
bound, E: GST-PBD pull-down) and total Rac1 in
WT versus Shank3+/DC mice. PBD, PAK1 protein-
binding domain. #p < 0.05, t test.
(F) Immunoblots and quantification (mean ± SEM)
showing actin in the Triton-soluble synaptic cyto-
solic fraction (G-actin) versus Triton-insoluble
synaptic membrane fraction (F-actin) from PFC of
WT versus Shank3+/DC mice. #p < 0.05, t test.
See also Figure S4.was significantly decreased (41.6% ± 7.0% decrease, n = 9
pairs, p < 0.01, t test), suggesting reduced Rac1 activity. More-
over, the downstream effectors of the Rac1 signaling cascade,
such as activated (Thr423/Thr402/Thr421-phosphorylated)
PAK1/2/3 and LIMK were significantly reduced in Shank3+/DC
mice (p-PAK: 22% ± 7% decrease, n = 17 pairs; LIMK: 25% ±
5% decrease, n = 11 pairs, p < 0.01, t test). A key downstream
target of PAK/LIMK signaling is cofilin, themajor actin depolyme-1404 Cell Reports 11, 1400–1413, June 9, 2015 ª2015 The Authorsrizing factor (Bamburg, 1999), which is in-
activated by phosphorylation at Ser3 (dos
Remedios et al., 2003). Shank3+/DC mice
had the unchanged total cofilin (n = 13
pairs, p > 0.05, t test), but a significantly
decreased level of the inactive (Ser3-
phosophorylated) form of cofilin (p-cofilin:
30% ± 5% decrease, n = 13 pairs, p <
0.01, t test), indicating that the active
form of cofilin is elevated in the cortex of
Shank3-deficient mice.
Given that Shank3 directly interacts
with the Arp2/3 complex to increase
F-actin levels in transgenic mice overex-
pressing Shank3 (Han et al., 2013), we
also examined the Arp2/3 activator
WAVE1/3, which is involved in actin
filament assembly. As shown in Figures
3A and 3B, no significant differences
were found in the expression of WAVE1
(n = 16 pairs, p > 0.05, t test) or WAVE3(n = 9 pairs, p > 0.05, t test) in cortical lysates from Shank3+/DC
mice.
We then examined the alteration of actin regulators in the cyto-
solic fraction of synapses from PFC of Shank3+/DC mice. As
shown in Figure 3C, the levels of synaptic p-PAK (active) and
p-cofilin (inactive) were significantly reduced (p-PAK: 38.6% ±
10.5% decrease, n = 8 pairs, p < 0.01, t test, p-cofilin:
37.3% ± 11.0% decrease, n = 5 pairs, p < 0.01, t test), indicating
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Figure 4. Shank3-Deficient Mice Have the
Reduced F-actin Level in Prefrontal Cortex,
Which Is Restored by Inhibition of Cofilin
(A) High-magnification confocal images (403) of
F-actin staining with phalloidin (co-stained with
PSD-95 and DAPI) in PFC slices of WT versus
Shank3+/DC mice without or with an i.v. injection of
the brain-permeable cofilin inhibitory peptide,
TAT-p-cofilin peptide (15 pmol/g). Scale bars,
50 mm. Shown at the top are low-magnification
(53) images of F-actin staining in semi-sagittal
slices of WT versus Shank3+/DC mice.
(B) Quantification (mean ± SEM) of F-actin and
PSD-95 levels (integrated densities) in PFC slices
of different animal groups. *p < 0.01, one-way
ANOVA.
(C) Representative images of Golgi-stained apical
dendrites in PFC pyramidal neurons from WT and
Shank3+/DC mice. Scale bar, 2 mm.
(D) Quantification (mean ± SEM) of apical and
basal dendritic spine densities in PFC neurons
from WT versus Shank3+/DC mice.
See also Figures S2 and S3.that PAK/cofilin signaling is aberrant in the synapses of PFC neu-
rons from Shank3-deficient mice.
Next, we examined whether the activity of Rac1, which is up-
stream of PAK/cofilin signaling, is altered in PFC of Shank3+/DC
mice. Cell line studies have found that bPIX specifically binds
the C-term of Rac1, but not of Cdc42 or RhoA, and the interac-
tion with bPIX is required for the membrane targeting and local-
ized activation of Rac1 (ten Klooster et al., 2006), so we
performed co-immunoprecipitation experiments to examine
bPIX-bound (active) Rac1 in PFC slices. As shown in Fig-
ure 3D, the Rac1-bPIX complex was significantly decreased inCell Reports 11, 1400–14Shank3+/DC mice (46% ± 10% decrease,
n = 7 pairs, p < 0.05, t test), suggesting
that Rac1 activity is decreased by Shank3
deficiency.
To further measure active Rac1
directly, we performed pull-down assay
using the purified GST-PAK1 protein-
binding domain (PBD) that specifically in-
teracts with GTP-bound Rac1 GTPase.
As shown in Figure 3E, compared to
wild-type counterparts, the level of active
Rac1 was significantly lower in PFC of
Shank3+/DC mice (51% ± 11% decrease,
n = 4 pairs, p < 0.05, t test).
The increased active cofilin may lead
to the alteration of actin filaments in
Shank3+/DC mice, so we compared the
Triton-soluble monomeric actin (G-actin)
and the Triton-insoluble filamentous poly-
merized actin (F-actin) in the synaptic
fraction of frontal cortex from WT versus
Shank3+/DC mice, using the approach
similar to what was previously described
(Fukazawa et al., 2003). We found thatthe level of total actin or actin at the synaptic cytosol (soluble)
was largely unchanged, but the level of synaptic F-actin (insol-
uble) in PFC of Shank3-deficient mice was significantly lower,
compared to WT counterparts (Figure 3F, 33.1% ± 10.4%
decrease, n = 6 pairs, p < 0.05, t test).
Tomore directly visualize F-actin, we performed immunostain-
ing with phalloidin. As shown in Figures 4A and 4B, Shank3-defi-
cient mice had a significant decrease of F-actin expression in
PFC slices (integrated density, WT: 100 ± 2.9, n = 9 mice/54 im-
ages; Shank3+/DC: 62.1 ± 3.9, n = 8 mice/49 images, p < 0.01,
ANOVA). In contrast to the reduced F-actin level, Shank3+/DC13, June 9, 2015 ª2015 The Authors 1405
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Figure 5. Inhibition of Cofilin Rescues ASD-like Behaviors and Restores NMDAR Function in Shank3-Deficient Mice
(A) Bar graphs (mean ± SEM) showing the time spent investigating either the social (Soc1) or nonsocial (NS1) stimulus during phase 2 of sociability testing in
Shank3+/DC mice with an i.v. injection of TAT-p-cofilin peptide or TAT control peptide (15 pmol/g). *p < 0.01, control versus p-cofilin peptide; #p < 0.001, ##p <
0.01, Soc1 versus NS1, two-way ANOVA.
(B) Plots (mean ± SEM) of social preference index (phase 2) in Shank3+/DC mice with an i.v. injection of TAT-p-cofilin peptide or TAT control peptide at different
time points. *p < 0.001, control versus p-cofilin peptide; #p < 0.001, pre- versus post-injection, two-way rmANOVA.
(C) Plots (mean ± SEM) of the time engaged in self-grooming behavior in Shank3+/DC mice with an i.v. injection of TAT-p-cofilin peptide or TAT control peptide at
different time points. *p < 0.05, control versus p-cofilin peptide; #p < 0.001, pre- versus post-injection, two-way rmANOVA.
(D) Bar graphs (mean ± SEM) showing the preference index for investigating different stimuli at three phases of sociability testing in Shank3+/DC mice with a local
(PFC) injection of TAT-p-cofilin peptide (5 mM, 1 ml per side) or TAT control peptide. *p < 0.01, t test.
(E and F) Bar graphs (mean ± SEM) of the NMDAR- to AMPAR-EPSC ratio (E) and input-output curves (mean ± SEM) of NMDAR-EPSC (F) in PFC pyramidal
neurons from WT versus Shank3+/DC mice receiving a systemic injection of TAT-p-cofilin peptide or TAT control peptide (15 pmol/g, i.v.). Recordings were
performed at 1 or 5 days post-injection. *p < 0.01, one-way ANOVA (E). *p < 0.05, two-way ANOVA (F).
(legend continued on next page)
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mice had normal PSD-95 expression in PFC (WT: 100 ± 4.2, n = 4
mice/35 images; Shank3+/DC: 112.9 ± 17.1, n = 4 mice/36 im-
ages; p > 0.05, t test), suggesting that the number of synapses
was intact. Hippocampal slices from Shank3+/DC mice also ex-
hibited a smaller but significant reduction of F-actin (Figure S2B,
WT: 100 ± 2.2, n = 10 mice/43 images; Shank3+/DC: 78.6 ± 5.6,
n = 7 mice/26 images, p < 0.01, t test). No significant alteration
of F-actin was observed in dorsal striatal slices from Shank3+/DC
mice (Figure S3B, WT: 100 ± 2.9, n = 6 mice/34 images;
Shank3+/DC: 100 ± 5.9, n = 5 mice/26 images, p > 0.05, t test),
which may be due to the lack of changes in bPIX expression in
the striatum of Shank3+/DC mice (Figure S3C, n = 5 pairs, p >
0.05, t test). These data suggest that Shank3 deficiency mainly
causes a cortical region-specific loss of actin filaments.
To restore cortical actin filaments, we used a peptide con-
sisting of one to 16 residues of Ser3-phosphorylated cofilin
as an inhibitor of endogenous cofilin (Morishita et al., 2005).
The p-cofilin peptide was coupled to the protein transduction
domain of the HIV TAT protein to render it cell permeable.
Since systemic injections can reliably deliver TAT peptides
into CNS neurons (Aarts et al., 2002; Borsello et al., 2003),
we gave Shank3+/DC mice an intravenous (i.v.) injection of
TAT-p-cofilin peptide (15 pmol/g). As shown in Figures 4A
and 4B, F-actin in Shank3+/DC mice was increased to the
normal level after a single injection of the cofilin inhibitory pep-
tide (113.7 ± 18.8, n = 5 mice/32 images, p < 0.01, ANOVA,
compared to Shank3+/DC) and remained elevated even at
4 days post-injection (90.7 ± 12.3, n = 7 mice/55 images).
Taken together, these data indicate that Shank3 deficiency
leads to increased cofilin activity and actin depolymerization,
which may contribute to the impaired NMDAR trafficking and
ASD-like behavioral deficits.
To test whether the number of synapses was altered in
Shank3+/DC mice, Golgi staining was performed to examine den-
dritic spines on PFC pyramidal neurons from WT versus
Shank3+/DC mice. No significant changes were observed in the
spine densities (# of spines/10 mm) on apical or basal dendrites
(Figures 4C and 4D, apical, WT: 7.37 ± 0.33, Shank3+/DC:
7.30 ± 0.57; basal, WT: 6.85 ± 0.32, Shank3+/DC: 6.74 ± 0.42,
n = 15–20 neurons/three pairs of mice, p > 0.05, t test), indicating
that the reduced F-actin in frontal cortex of Shank3-deficient
mice did not lead to an obvious loss of synapses.
In addition, we examined whether changes in actin signaling
can be found in an independent Shank3-deficient mouse line.
Mice with a targeted disruption of Shank3 exons coding for the
N-terminal ankyrin repeat domain, which leads to the loss of
the longest isoforms of Shank3 (Shank3-KO; Bozdagi et al.,
2010), were used. We carried out unbiased analyses using
two-dimensional fluorescence difference gel electrophoresis
(2D-DIGE). Triplicate comparisons identified several spots
showing differential expression between cortical PSD fractions(G) Input-output curves (mean ±SEM) of NMDAR-EPSC in PFC pyramidal neurons
or TAT control peptide to PFC. *p < 0.01, ANOVA.
(H and I) Immunoblots and quantification (mean ±SEM) of the expression of NR1 a
from WT versus Shank3+/DC mice injected with TAT-p-cofilin peptide or TAT cont
injection. #p < 0.05, *p < 0.01, ANOVA.
See also Figures S5 and S6 and Movies S4, S5, S6, and S7.
Cfrom WT and Shank3-KO, including actin-binding proteins (Fig-
ure S4A). To validate the finding in an independent cohort, immu-
noblot analyses were performed in PSD fractions from additional
WT and Shank3-KO mice. As shown in Figure S4B, Shank3-KO
mice had a significant reduction of Ser3p-cofilin (inactive cofilin,
60% ± 2.7% decrease, n = 4 pairs, p < 0.01, t test) and LIMK1
(a kinase responsible for cofilin phosphorylation and inactivation,
35% ± 4.8% decrease, n = 4 pairs, p < 0.01, t test), consistent
with our findings in Shank3+/DC mice.
Inhibiting Cofilin to Stabilize F-actin Rescues Behavioral
Deficits and Restores NMDAR Function in Shank3-
Deficient Mice
Since male Shank3+/DC mice have a prominent reduction of
cortical actin filaments, which can be rescued by the TAT-p-
cofilin peptide (Figure 4), we further examined whether the
ASD-like behavioral deficits in these mice could be rescued by
cofilin inhibition. Behavioral tests found that after the i.v. injection
of TAT-p-cofilin peptide (15 pmol/g), but not TAT control peptide,
Shank3-deficient mice displayed a significant increase in the
preference of exploring the social stimulus over the non-social
object in phase 2 of sociability tests (Figure 5A, p-cofilin peptide,
social: 107.6 ± 7.5 s, nonsocial: 22.4 ± 0.9 s, n = 9; TAT control
peptide, social: 73.0 ± 8.2 s, nonsocial: 40.5 ± 4.8 s, n = 11;
F1,36 (interaction) = 17.5, p < 0.01, two-way ANOVA). The signifi-
cantly increased social preference index (Soc1-NS1, phase 2)
in Shank3+/DC mice induced by the p-cofilin peptide (Figure 5B,
p-cofilin peptide, pre-injection: 31.7% ± 3.9%, 1–2 hr post-injec-
tion: 62.1% ± 2.8%, 4 days post-injection: 62.7% ± 3.1%, n =
12; TAT control peptide, pre-injection: 21.5% ± 1.8%, 1–2 hr
post-injection: 20.5% ± 5.4%, 4 days post-injection: 13.6% ±
2.9%, n = 8; F2,36 (interaction) = 13.8, p < 0.0001, two-way
repeated-measure ANOVA [rmANOVA]) demonstrated a restora-
tion of sociability with cofilin inhibition. The fast and long-lasting
rescue of social deficits can be clearly seen in Movies S4, S5,
and S6. The peptide injection did not cause any significant
changes in non-social (NS1-NS1, phase 1) or novel social
(Soc2- Soc1, phase 3) tests at any time point (data not shown).
To test the effectiveness of cofilin inhibition in rescuing other
ASD-like behaviors, we examined self-grooming in Shank3-defi-
cientmice. As shown in Figure 5C, Shank3+/DCmice injected (i.v.)
with TAT-p-cofilin peptide, but not TAT control peptide, had a
significant decrease in self-grooming time (p-cofilin peptide,
pre-injection: 105.3 ± 15.6 s, 1–2 hr post-injection: 36.0 ±
6.4 s, 4 days post-injection: 29.0 ± 5.3 s, n = 8; control peptide,
pre-injection: 89.4 ± 14.0 s, 1–2 hr post-injection: 103.0 ± 12.1 s,
4 days post-injection: 97.1 ± 12.6 s, n = 8; F2,28 (interaction) = 19.8,
p < 0.0001, two-way rmANOVA, see Movie S7).
We further performed the bilateral stereotaxic injection of the
cofilin inhibitory peptide into prelimbic regions of Shank3-defi-
cient mice and examined sociability rescue. Shank3+/DC micefromWT versus Shank3+/DCmice with a local injection of TAT-p-cofilin peptide
nd NR2A in the Triton-insoluble synaptosomal fraction of frontal cortical tissues
rol peptide (15 pmol/g, i.v.). Western blots were performed at 1 or 4 days post-
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receiving the PFC injection of p-cofilin peptide, but not TAT con-
trol peptide, displayed a significant increase in the preference of
exploring the social stimulus over non-social object in phase 2 of
sociability tests (p-cofilin peptide, social: 144.0 ± 5.2 s, nonso-
cial: 25.6 ± 1.5 s, n = 7; control peptide, social: 78.8 ± 12.6 s,
nonsocial: 62.0 ± 13.8 s, n = 5, F1,20 (interaction) = 36.7, p <
0.0001, two-way ANOVA). The significantly increased social
preference index in Shank3+/DC mice after cofilin inhibition
in PFC (Figure 5D, TAT control peptide: 15.2% ± 4.6%, n = 5,
p-cofilin peptide: 69.9% ± 0.9%, n = 7, p < 0.001, t test) sug-
gested the restored social interactions.
The systemic administration of cofilin inhibitory peptide led
to the recovery of social behavior in Shank3+/DC mice, which
was consistent in each of the animals tested (Figure S5B). To
determine whether the peptide may induce any side effects,
we examined more behavioral tasks. As shown in Figure S5C,
wild-type or Shank3+/DC mice injected (i.v.) with TAT-p-cofilin
peptide (15 pmol/g) exhibited normal performance in locomo-
tion, open-field, and rotarod tests (n = 8–10 each group). The so-
cial preference was also unchanged in wild-type mice injected
with TAT-p-cofilin peptide (WT: 62.7% ± 4.2%, n = 4, WT+p-
cof pep: 59.9% ± 2.6%, n = 5). From the Movies S4, S6, and
S7, it is also evident that Shank3+/DCmice injectedwith the cofilin
inhibitory peptide did not exhibit any behavioral abnormality or
health problems, indicating that this reagent did not lead to the
collapse of actin network in all cell types and induce unwanted
side effects.
Furthermore, we examined the dose response of p-cofilin pep-
tide. Administration (i.v.) of a low-dose p-cofilin peptide, which
is 100-fold lower than the effective dose, 0.15 pmol/g, to
Shank3+/DC mice was incapable of ameliorating the social
deficits (Figure S5D, phase 2, WT: 56.9% ± 1.9%, n = 4;
Shank3+/DC: 11.9% ± 8.3%, n = 5, p < 0.01, t test) or repetitive
grooming behaviors (Figure S5D, WT: 25.8 ± 10.4 s, n = 4;
Shank3+/DC: 104.0 ± 24.1 s, n = 5, p < 0.05, t test).
Next, we tested whether inhibiting the activity of cofilin to
block actin depolymerization could restore NMDAR function in
Shank3-deficient mice. The NMDAR- to AMPAR-EPSC ratio in
PFC neurons of Shank3+/DC mice was significantly increased
following (1 day) an i.v. injection of cofilin inhibitory peptide (Fig-
ure 5E, TAT control: 0.48 ± 0.03, n = 9, p-cofilin peptide: 0.68 ±
0.02, n = 10, F3,30 = 23.2, p < 0.01, one-way ANOVA), which was
at the level similar to PFC neurons of wild-typemice injectedwith
TAT control peptide (0.73 ± 0.03, n = 7). The p-cofilin peptide-
induced recovery even persisted at 5 days post-injection
(0.66 ± 0.02, n = 8, p < 0.05). Similarly, the input/output curves
of NMDAR-EPSC also showed strong and sustained recovery
in PFC neurons of Shank3+/DC mice with an i.v. injection
of TAT-p-cofilin peptide (Figure 5F, n = 20–24 each group,
F3,415 (treatment) = 26.6, p < 0.001, two-way ANOVA). Furthermore,
Shank3+/DCmicewith the stereotaxic injection of cofilin inhibitory
peptide into PFC exhibited the significantly elevated NMDAR- to
AMPAR-EPSC ratio (TAT control: 0.47 ± 0.04, n = 7, p-cofilin:
0.66 ± 0.04, n = 10, p < 0.05, t test) and NMDAR-EPSC input/
output curves (Figure 5G, 50%–70% increase, n = 11–12 each
group, F1,105 (treatment) = 33.8, p < 0.001, two-way ANOVA).
Biochemical experiments were also performed to examine the
effect of cofilin inhibitor on synaptic NMDAR subunits in Shank3-1408 Cell Reports 11, 1400–1413, June 9, 2015 ª2015 The Authorsdeficient mice. As shown in Figures 5H and 5I, an injection (i.v.) of
TAT-p-cofilin peptide (15 pmol/g) significantly elevated the levels
of NR1 and NR2A in the synaptic membrane fraction of frontal
cortical tissues of Shank3+/DC mice, and this rescuing effect
could still be observed at 4 days after injection (n = 4–7 per group,
p > 0.05, ANOVA, compared to WT). Taken together, these re-
sults suggest that inhibiting cofilin to stabilize F-actin in PFC is
able toprovide a sustained rescueof theASD-like behavioral def-
icits and NMDAR hypofunction in Shank3-deficient mice.
Additional electrophysiological experiments found that wild-
typemice injected (i.v.) with TAT-p-cofilin peptide had largely un-
changed NMDAR-EPSC in PFC neurons (Figure S6A, n = 16
pairs, F1,155 = 1.7, p > 0.05, two-way ANOVA) or striatal neurons
(Figure S6B, n = 12 pairs, F1,120 = 1.9, p > 0.05, two-way ANOVA).
Repetitive (once daily, 4 days) injections (i.v.) of TAT-p-cofilin
peptide also led to the robust recovery of NMDAR-EPSC in
PFC neurons of Shank3+/DC mice (Figure S6C, n = 17–18 each
group, F1,160 (treatment) = 25.3, p < 0.001, two-way ANOVA).
Restoration of NMDAR-EPSC in hippocampal CA1 neurons of
Shank3+/DC mice was also observed with an i.v. injection of
TAT-p-cofilin peptide (Figure S6D, n = 7–9 each group, F2,100 =
2.2, p > 0.05, two-way ANOVA). Moreover, NMDAR-EPSC was
not restored by the low-dose p-cofilin peptide (Figure S6E,
F1,80 = 22.8, n = 8–10 each group, p < 0.001, two-way
ANOVA), probably due to its inability to inhibit cofilin activity.
PAK and Rac1 Are Involved in ASD-like Behavioral and
Physiological Changes
One of the main upstream kinases for cofilin is PAK. PAK, by
phosphorylating cofilin via LIMK, inhibits the ability of cofilin to
depolymerize F-actin (Sells et al., 1997; Arber et al., 1998).
Thus, we examined the role of PAK in ASD-like social behaviors.
To inhibit PAK activity, we used PAK18, a 18-mer peptide against
the proline-rich domain of PAK that blocks the PAK-PIX interac-
tion essential for the PAK activation (Maruta et al., 2002). TAT-
PAK18 (15 pmol/g) was i.v. injected into wide-type mice,
followed by the test of social preference. Biochemical assays
demonstrated that TAT-PAK18 peptide injection induced a sig-
nificant reduction of endogenous PAK activity (p-PAK) and the
downstream p-cofilin (inactive) level in PFC (Figures 6A and
6B). After TAT-PAK18 peptide injection, wild-type mice dis-
played a significant decrease in the preference of exploring the
social stimulus over non-social object in phase 2 of sociability
tests (Figure 6C, PAK18 peptide, social: 82.5 ± 7.0 s, nonsocial:
41.6 ± 3.3 s, n = 11; TAT control peptide, social: 172.3 ± 7.7 s,
nonsocial: 38.7 ± 5.9 s, n = 9, F1,36 (interaction) = 57.6, p <
0.0001, two-way ANOVA). The significantly decreased social
preference index (phase 2) in WT mice after PAK inhibition (Fig-
ure 6D, TAT: 64.0% ± 4.5%, n = 9; PAK18: 31.5% ± 4.7%,
n = 11, p < 0.01, t test) suggested the decreased social affiliation.
In parallel with the induction of ASD-like behavioral deficits
with PAK inhibition, the synaptic NMDAR function was also
significantly diminished in PFC neurons from wild-type mice in-
jected with PAK18 peptide (Figure 6E, 20%–30% decrease,
n = 11–12 each group, F1,105 (treatment) = 31.7, p < 0.001, two-
way ANOVA). These data suggest that PAK inhibition could
lead to behavioral and physiological impairment reminiscent of
autism.
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Figure 6. Inhibition of PAK Induces Social Deficits and NMDAR
Hypofunction in Wild-Type Mice
(A and B) Immunoblots and quantification (mean ± SEM) of p-PAK, PAK1,
p-cofilin, and cofilin in PFC slices from WT mice injected with TAT-PAK18
inhibitory peptide (15 pmol/g, i.v.) or TAT control peptide. *p < 0.05, **p < 0.01,
t test.
(C and D) Bar graphs (mean ±SEM) showing the time spent investigating either
the social or nonsocial stimulus during phase 2 of sociability testing (C) and the
preference index at three phases of sociability testing (D) in WT mice injected
with TAT-PAK18 or TAT control peptide. *p < 0.001, control versus PAK18
peptide; #p < 0.001, ##p < 0.01, Soc1 versus NS1, two-way ANOVA (C). *p <
0.01, t test (D).
(E) Input-output curves (mean ± SEM) of NMDAR-EPSC in WT mice injected
with TAT-PAK18 or TAT control peptide. #p < 0.05, ANOVA. Inset: represen-
tative NMDAR-EPSC traces.
Scale bars, 40 pA, 200 ms.
COne of the major upstream regulators of PAK involved in actin
cytoskeletal rearrangements is Rac1. To examine the role of
Rac1 in autism, wemanipulated the activity of Rac1 using herpes
simplex virus (HSV)-mediated gene transfer (Dietz et al., 2012).
HSV constructs containing fluorescent protein-tagged domi-
nant-negative Rac1 (DN-Rac1) or constitutively active Rac1
(CA-Rac1) were bilaterally injected into prelimbic regions (Fig-
ure 7A). Viral expression of DN-Rac1 in wild-type mice induced
ASD-like social deficits in the three-chamber social interaction
assay, which was reflected by a significantly lower preference in-
dex for the social stimulus over the non-social object in phase 2
(Figure 7B, GFP control in WT: 57.4% ± 4.6%, n = 7; DN-Rac1 in
WT: 16.2% ± 6.7%, n = 6, p < 0.001, t test). Conversely, viral
expression of CA-Rac1 in Shank3+/DC mice rescued the ASD-
like social deficits in the three-chamber social interaction assay,
which was reflected by a significantly higher preference index for
the social stimulus over the non-social object in phase 2 (Fig-
ure 7C, GFP control in Shank3+/DC: 16.1% ± 3.7%, n = 4; CA-
Rac1 in Shank3+/DC: 67.5% ± 2.0%, n = 4, p < 0.001, t test).
Electrophysiological experiments were also performed on
mice with in vivo manipulation of Rac1 activity in PFC. As shown
in Figure 7D, NMDAR-EPSCwasmarkedly reduced in PFC pyra-
midal neurons from WT mice injected with DN-Rac1 HSV (30%–
40% decrease, n = 12–14 each group, F1,120 (treatment) = 50.2,
p < 0.001, two-way ANOVA). Furthermore, NMDAR-EPSC
was significantly increased in PFC pyramidal neurons from
Shank3+/DC mice injected with CA-Rac1 HSV (Figure 7E, 40%–
60% increase, n = 14–15 each group, F1,135 (treatment) = 28.9,
p < 0.001, two-way ANOVA). Taken together, these results sug-
gest that the ASD-like behavioral and physiological deficits can
be induced by Rac1 inhibition in normal animals, and can be
rescued by Rac1 activation in Shank3-deficient conditions.
DISCUSSION
Transcriptomic analyses of ASD brains have revealed that gene
mutations that lead to synaptic and neuronal signaling dysfunc-
tion are a convergent molecular pathology of autism (Voineagu
et al., 2011; Gilman et al., 2011). The gene expression changes
associated with ASD are most pronounced in the frontal cortex
(Voineagu et al., 2011). The impairments of PFC-mediated exec-
utive functions in individuals with ASD, including cognitive
flexibility, social interaction, inhibition, planning, and attention
(Anderson et al., 1999; Hill, 2004), suggest that genetic changes
that cause synaptic dysfunction in frontal cortex may be at the
heart of autism.
The Shank3 gene, located on chromosome 22q13.3 in hu-
mans, was first implicated in ASD from genetic analysis of the
22q13.3 microdeletion syndrome. Heterozygous mutations in
Shank3 gene cause ASD in a gene-dosage dependent manner
(Durand et al., 2007; Sebat et al., 2007). Heterozygous mice ex-
pressing C-terminal deleted Shank3, Shank3+/DC, had a marked
deficiency of the endogenous full-length Shank3 isoforms (Fig-
ure 1A), providing a model of autism with the loss of naturally
occurring Shank3 proteins. Interestingly, we found that juvenile
male Shank3-deficient mice exhibited ASD-like behavioral defi-
cits, including social interaction deficiency (Figures 1B and 1C)
and repetitive grooming (Figure 1D). Some of the phenotypesell Reports 11, 1400–1413, June 9, 2015 ª2015 The Authors 1409
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Figure 7. Social Deficits and NMDAR Hypo-
function Are Induced by Suppressing
Rac1 Activity inWild-TypeMice and Rescued
by Elevating Rac1 Activity in Shank3-Defi-
cient Mice
(A) A low-magnification (53) image of a coronal
slice showing the GFP HSV-infected medial PFC
region. Inset: a confocal image (403) of HSV-
infected PFC neurons.
(B and C) Bar graphs (mean ± SEM) showing the
preference index for three phases of sociability
testing in WT mice with PFC injection of dominant-
negative Rac1 (DN-Rac1) HSV (B), or in Shank3+/DC
mice with PFC injection of constitutively active
Rac1 (CA-Rac1) HSV (C). GFP HSV was used as a
control. *p < 0.01, t test.
(D and E) Input-output curves (mean ± SEM) of
NMDAR-EPSC in WT mice with PFC injection of
DN-Rac1 HSV (D) or in Shank3+/DC mice with PFC
injection of CA-Rac1 HSV (E). *p < 0.01, ANOVA.have also been observed in animals carrying other Shank3 dele-
tions/mutations (Jiang and Ehlers, 2013). However, the pheno-
types of Shank3 mutant mice are not always consistent, with
either significant (Wang et al., 2011; Pec¸a et al., 2011) or mild
(Bozdagi et al., 2010; Kouser et al., 2013) social deficits being re-
ported. Potential contributing factors for the discrepancy include
the different locations of the Shank3 gene mutation and the
different methods utilized in habituating and testing animals.
Blocking NMDA receptors in the PFC of wild-type mice
induced ASD-like social deficits (Figures 1E and 1F), suggesting
that the behavioral abnormality in Shank3+/DC mice might be
caused by NMDAR hypofunction. In agreement with this, we
have found a selective loss of NMDAR-mediated synaptic
response in PFC neurons of Shank3+/DC mice (Figures 2A–2C).
Consistently, homozygous Shank3DC/DC mice exhibit reduced
NMDAR to AMPAR-EPSC ratio and impairments in hippocampal
synaptic transmission and plasticity (Kouser et al., 2013). Drugs
acting at the glycine site on the NMDAR to enhance its function
have been found to have therapeutic potential for autism
treatment (Won et al., 2012). The NMDAR hypofunction in
Shank3+/DC mice was associated with the reduced level of
synaptic NMDAR subunits (Figures 2D and 2E), suggesting
the impairment of NMDAR synaptic trafficking by Shank3
deficiency.
Previous studies have shown that NMDARmembrane delivery
and stability is dependent on the integrity of actin cytoskeleton
(Rosenmund andWestbrook, 1993; Allison et al., 1998; Morishita
et al., 2005; Duffney et al., 2013). Abnormalities in Rho GTPase
signaling, which orchestrate coordinated changes in actin as-
sembly and organization (Hall, 1998; Calabrese et al., 2006),
have been identified as a prominent cause of mental retardation1410 Cell Reports 11, 1400–1413, June 9, 2015 ª2015 The Authors(Allen et al., 1998; Ramakers, 2002). Shank
forms a complex with bPIX, the GEF
involved in Rac1 activation, and overex-
pression of Shank in cultured neurons
promotes synaptic accumulation of bPIX
(Park et al., 2003). We found that, in
cortical slices of Shank3+/DC mice (Fig-ure 3), the expression of bPIX was strongly reduced, which led
to the decreased Rac1 activity. The Rac1 downstream effectors,
active (phosphorylated) PAK and LIMK, were significantly
reduced in Shank3+/DC mice. Moreover, cofilin, the major actin
depolymerizing factor that is phosphorylated and inactivated
by PAK/LIMK signaling, was disinhibited. Consequently, the
level of F-actin was substantially decreased in PFC of Shank3-
deficient mice, which was likely due to the increased cofilin
activity (Figure 4). Examination of actin signaling in another
Shank3-deficient mouse line that lacks the longest isoforms of
Shank3 also demonstrated multiple changes in actin signaling
including decreased LIMK and phosphorylated (inactive) cofilin
(Figure S4B).
In corroboration with our results, overexpression of Shank3
has been found to enhance actin polymerization (Durand et al.,
2012) and increase F-actin levels (Han et al., 2013). The alter-
ations of actin regulators in Shank3 models of autism identified
in this study also supports the genetic analysis of autistic brains,
which suggests that autism-associated de novo variants
converge on the genes involved in the regulation of actin fila-
ments and the formation and function of synapses (Gilman
et al., 2011).
To determinewhether the dysregulation of synaptic actin cyto-
skeleton drives autistic phenotypes inShank3-deficient mice, we
perturbed key actin regulators. Inhibition of cofilin activity pro-
duced a robust and long-lasting rescue of the social interaction
deficits and repetitive behavior in Shank3+/DC mice (Figure 5),
which correlated well with the restoration of NMDAR function,
suggesting a promising therapeutic strategy for autism treat-
ment. No behavioral abnormality or health problems have been
observed in Shank3+/DC mice injected with the cofilin inhibitory
peptide, suggesting that it is a safe and effective intervention.
Although local injections of the cofilin inhibitor to prefrontal cor-
tex of Shank3+/DCmice led to similar rescue of autistic behaviors,
systemic (i.v.) injections provide a much more feasible therapeu-
tic approach.
Inhibiting PAK or Rac1 function in wild-type animals produced
ASD-like social deficits andNMDARhypofunction (Figures 6, 7B,
and 7D), confirming the importance of Rac1/PAK signaling in
autism. Indeed, elevating Rac1 activity in PFC of Shank3-defi-
cient mice also led to the rescue of behavioral and NMDAR
abnormality (Figures 7C and 7E), providing another molecular
target for autism treatment.
Given the universal expression of actin in all cell types, one
concern is the potential non-specific effects generated by actin
manipulating agents. However, some actin regulators are largely
brain specific, such as the ASD risk gene CTTNBP2 (De Rubeis
et al., 2014), which interacts with the F-actin-binding protein
Cortactin (a Shank3 binding protein). Actin filament is highly en-
riched and forms a uniquely dynamic structure in dendritic
spines of neurons (Frost et al., 2010), serving a special role to
regulate the formation, maintenance, and function of glutamater-
gic synapses during development and at mature stages (Matus,
2000; Hotulainen and Hoogenraad, 2010). Different postsynaptic
proteins are differentially affected by actin dynamics, with
NMDARs being very sensitive to the state of actin depolymeriza-
tion. Moreover, Shank3 directly links NMDARs to actin cytoskel-
eton, making NMDARs particularly sensitive to Shank3-induced
changes in actin dynamics. It is probably the reason why
AMPARs, which can also be regulated by actin (Rocca et al.,
2008; Yuen et al., 2010), are not significantly affected in
Shank3-deficient neurons. High-throughput gene expression
profiling has found that different actin interacting proteins have
distinct transcriptional activity in different brain regions and
non-CNS areas, thus targeting the actin regulators highly
restricted to PFC, such as human PAK3, whosemutation causes
X-linked mental retardation (Allen et al., 1998), will enable the
specific normalization of actin dynamics at PFC glutamatergic
synapses.
In summary, our convergent evidence has revealed actin dys-
regulation and ensuing NMDAR hypofunction in pyramidal neu-
rons of prefrontal cortex as a pathophysiological basis for the
ASD-like behaviors in a Shank3 model of autism. Normally,
Shank3 crosslinks NMDARs to the actin cytoskeleton. Loss of
Shank3 leads to the reduced expression of bPIX (GEF for
Rac1) and reduced Rac1/PAK/LIMK signaling, which results in
the increased cofilin activity (due to reduced cofilin phosphoryla-
tion). Consequently, actin depolymerization is increased, leading
to disrupted NMDAR synaptic delivery through the actin cyto-
skeleton. The loss of functional NMDARs in PFC contributes to
autism-like social deficits. In support of our findings, anatomical
studies have found focal patches of abnormal organization in
prefrontal cortex of autistic children, with the clearest deficits
in the expression of markers of excitatory cortical neurons in
layers 4 and 5 (Stoner et al., 2014). Genetic analyses have found
enriched mutations in genes regulating actin filament network at
glutamatergic synapses in autism (Gilman et al., 2011). Our re-
sults also suggest that perturbing the signaling molecules in
Rac1/PAK/cofilin pathway to normalize cortical actin dynamicsCoffers a potential therapeutic strategy to ameliorate behavioral
and synaptic defects in autism.
EXPERIMENTAL PROCEDURES
All experiments were performed with the approval of the Institutional Animal
Care and Use Committee of the State University of New York at Buffalo.
Behavioral Testing and Animal Surgery
The mice expressing C-terminal (exon 21) deleted Shank3 (Jackson Labora-
tory) were generated as previously described (Kouser et al., 2013). Heterozy-
gous Shank3+/DCmice (6–8 weeks old, male) and age-matched wild-typemice
(C57BL/6, male) were mainly used in this study. For details on behavioral as-
says, including social preference, locomotion, open-field, rotarod, and self-
grooming, and animal surgery details, see the Supplemental Experimental
Procedures.
Electrophysiological Recordings
Whole-cell voltage-clamp recording technique was used to measure synaptic
currents in layer 5 pyramidal neurons of prefrontal cortical slices, as previously
described (Yuen et al., 2012). See the Supplemental Experimental Procedures
for details.
Biochemical Measurements, Immunohistochemistry, and 2D-DIGE
See the Supplemental Experimental Procedures for details.
Statistics
All data are expressed as the mean ± SEM. Experiments with two groups were
analyzed statistically using unpaired Student’s t tests. Experiments with
more than two groups were subjected to one-way ANOVA, two-way
ANOVA, or two-way repeated-measure ANOVA (rmANOVA), followed by
post hoc Bonferroni tests.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental Results, Supplemental Discussion, seven figures, and seven
movies and can be found with this article online at http://dx.doi.org/10.1016/
j.celrep.2015.04.064.
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